|
|
| After the discovery of its extraordinary psychic effects, the substance
LSD-25, which five years earlier had been excluded from further investigation
after the first trials on animals, was again admitted into the series of
experimental preparations. Most of the fundamental studies on animals were
carried out by Dr. Aurelio Cerletti in the Sandoz pharmacological department,
headed by Professor Rothlin.
Before a new active substance can be investigated in systematic clinical
trials with human subjects, extensive data on its effects and side effects
must be determined in pharmacological tests on animals. These experiments must
assay the assimilation and elimination of the particular substance in
organisms, and above all its tolerance and relative toxicity. Only the most
important reports on animal experiments with LSD, and those intelligible to
the layperson, will be reviewed here. It would greatly exceed the scope of
this book if I attempted to mention all the results of several hundred
pharmacological investigations, which have been conducted all over the world
in connection with the fundamental work on LSD in the Sandoz laboratories.
Animal experiments reveal little about the mental alterations caused by LSD
because psychic effects are scarcely determinable in lower animals, and even
in the more highly developed, they can be established only to a limited
extent. LSD produces its effects above all in the sphere of the higher and
highest psychic and intellectual functions. It is therefore understandable
that speciflc reactions to LSD can be expected only in higher animals. Subtle
psychic changes cannot be established in animals because, even if they should
be occurring, the animal could not give them expression. Thus, only relatively
heavy psychic disturbances, expressing themselves in the altered behavior of
research animals, become discernible. Quantities that are substantially higher
than the effective dose of LSD in human beings are therefore necessary, even
in higher animals like cats, dogs, and apes.
While the mouse under LSD shows only motor disturbances and alterations in
licking behavior, in the cat we see, besides vegetative symptoms like
bristling of the hair (piloerection) and salivation, indications that point to
the existence of hallucinations. The animals stare anxiously in the air, and
instead of attacking the mouse, the cat leaves it alone or will even stand in
fear before the mouse. One could also conclude that the behavior of dogs that
are under the influence of LSD involves hallucinations. A caged community of
chimpanzees reacts very sensitively if a member of the tribe has received LSD.
Even though no changes appear in this single animal, the whole cage gets in an
uproar because the LSD chimpanzee no longer observes the laws of its finely
coordinated hierarchic tribal order.
Of the remaining animal species on which LSD was tested, only aquarium fish
and spiders need be mentioned here. In the fish, unusual swimming postures
were observed, and in the spiders, alterations in web building were apparently
produced by kSD. At very low optimum doses the webs were even better
proportioned and more exactly built than normally: however, with higher doses,
the webs were badly and rudimentarily made. |
| |
The toxicity of LSD has been determined in various animal species. A standard
for the toxicity of a substance is the LDso, or the median lethal dose, that
is, the dose with which 50 percent of the treated animals die. In general it
fluctuates broadly, according to the animal species, and so it is with LSD.
The LDso for the mouse amounts to 50-60 mgtkg i.v. (that is, 50 to 60
thousandths of a gram of LSD per kilogram of animal weight upon injection of
an LSD solution into the veins). In the rat the LDso drops to 16.5 mg/kg, and
in rabbits to 0.3 mg/kg. One elephant given 0.297 g of LSD died after a few
minutes. The weight of this animal was determined to be 5,000 kg, which
corresponds to a lethal dose of 0.06 mg/kg (0.06 thousandths of a gram per
kilogram of body weight). Because this involves only a single case, this value
cannot be generalized, but we can at least deduce from it that the largest
land animal reacts proportionally very sensitively to LSD, since the lethal
dose in elephants must be some 1,000 times lower than in the mouse. Most
animals die from a lethal dose of LSD by respiratory arrest.
The minute doses that cause death in animal experiments may give the
impression that LSD is a very toxic substance. However, if one compares the
lethal dose in animals with the effective dose in human beings, which is
0.0003-0.001 mg/kg (0.0003 to 0.001 thousandths of a gram per kilogram of body
weight), this shows an extraordinarily low toxicity for LSD. Only a 300- to
600-fold overdose of LSD, compared to the lethal dose in rabbits, or fully a
50,000- to 100,000fold overdose, in comparison to the toxicity in the mouse,
would have fatal results in human beings. These comparisons of relative
toxicity are, to be sure, only understandable as estimates of orders of
magnitude, for the determination of the therapeutic index (that is, the ratio
between the effective and the lethal dose) is only meaningful within a given
species. Such a procedure is not possible in this case because the lethal doge
of LSD for humans is not known. To my knowledge, there have not as yet
occurred any casualties that are a direct consequence of LSD poisoning.
Numerous episodes of fatal consequences attributed to LSD ingestion have
indeed been recorded, but these were accidents, even suicides, that may be
attributed to the mentally disoriented condition of LSD intoxication. The
danger of LSD lies not in its toxicity, but rather in the unpredictability of
its psychic effects.
Some years ago reports appeared in the scientific literature and also in the
lay press, alleging that damage to chromosomes or the genetic material had
been caused by LSD. These effects, however, have been observed in only a few
individual cases. Subsequent comprehensive investigations of a large,
statistically significant number of cases, however, showed that there was no
connection between chromosome anomalies and LSD medication. The same applies
to reports about fetal deformities that had allegedly been produced by LSD. In
animal experiments, it is indeed possible to induce fetal deformities through
extremely high doses of LSD, which lie well above the doses used in human
beings. But under these conditions, even harmless substances produce such
damage. Examination of reported individual cases of human fetal deformities
reveals, again, no connection between LSD use and such injury. If there had
been any such connection, it would long since have attracted attention, for
several million people by now have taken LSD. |
| |
LSD is absorbed easily and completely through the gastrointestinal tract. It
is therefore unnecessary to inject LSD, except for special purposes.
Experiments on mice with radioactively labeled LSD have established that
intravenously injected LSD disappeared down to a small vestige, very rapidly
from the bloodstream and was distributed throughout the organism.
Unexpectedly, the lowest concentration is found in the brain. It is
concentrated here in certain centers of the midbrain that play a role in the
regulation of emotion. Such findings give indications as to the localization
of certain psychic functions in the brain.
The concentration of LSD in the various organs attains maximum values 10 to 15
minutes after injection, then falls off again swiftly. The small intestine, in
which the concentration attains the maximum within two hours, constitutes an
exception. The elimination of LSD is conducted for the most part (up to some
80 percent) through the intestine via liver and bile. Only 1 to 10 percent of
the elimination product exists as unaltered LSD; the remainder is made up of
various transformation products.
As the psychic effects of LSD persist even after it can no longer be detected
in the organism, we must assume that LSD is not active as such, but that it
rather triggers certain biochemical, neurophysiological, and psychic
mechanisms that provoke the inebriated condition and continue in the absence
of the active principle.
LSD stimulates centers of the sympathetic nervous system in the midbrain,
which leads to pupillary dilatation, increase in body temperature, and rise in
the blood-sugar level. The uterine-constricting activity of LSD has already
been mentioned.
An especially interesting pharmacological property of LSD, discovered by J. H.
Gaddum in England, is its serotonin-blocking effect. Serotonin is a
hormone-like substance, occurring naturally in various organs of warm-blooded
animals. Concentrated in the midbrain, it plays an important role in the
propagation of impulses in certain nerves and therefore in the biochemistry of
psychic functions. The disruption of natural functioning of serotonin by LSD
was for some time regarded as an explanation of its psychic effects. However,
it was soon shown that even certain derivatives of LSD (compounds in which the
chemical structure of LSD is slightly modified) that exhibit no hallucinogenic
properties, inhibit the effects of serotonin just as strongly, or yet more
strongly, than unaltered LSD. The serotonin-blocking effect of LSD thus does
not suffice to explain its hallucinogenic properties.
LSD also influences neurophysiological functions that are connected with
dopamine, which is, like serotonin, a naturally occurring hormone-like
substance. Most of the brain centers receptive to dopamine become activated by
LSD, while the others are depressed.
As yet we do not know the biochemical mechanisms through which LSD exerts its
psychic effects. Investigations of the interactions of LSD with brain factors
like serotonin and dopamine, however, are examples of how LSD can serve as a
tool in brain research, in the study of the biochemical processes that
underlie the psychic functions. |
| |
| Lysergic acid proved to be a rather unstable substance, and its rebonding with
basic radicals posed difficulties. In the technique knon as Curtius'
Synthesis, I ultimately found a process that proved useful for combining
lysergic acid with amines. With this method I produced a great number of
lysergic acid compounds. By combining lysergic acid with the amino alcohol
propanolamine, I obtained a compound that was identical to the natural ergot
alkaloid ergobasine. With that, the first synthesis - that is, artificial
production - of an ergot alkaloid was accomplished. This was not only of
scientific interest, as confirmation of the chemical structure of ergobasine,
but also of practical significance, because ergobasine, the specifically
uterotonic, hemostatic principle, is present in ergot only in very trifling
quantities. With this synthesis, the other alkaloids existing abundantly in
ergot could now be converted to ergobasine, which was valuable in obstetrics.
After this first success in the ergot field, my investigations went forward on
two fronts. First, I attempted to improve the pharmacological properties of
ergobasine by variations of its amino alcohol radical. My colleague Dr. J.
Peyer and I developed a process for the economical production of propanolamine
and other amino alcohols. Indeed, by substitution of the propanolamine
contained in ergobasine with the amino alcohol butanolamine, an active
principle was obtained that even surpassed the natural alkaloid in its
therapeutic properties. This improved ergobasine has found worldwide
application as a dependable uterotonic, hemostatic remedy under the trade name
Methergine, and is today the leading medicament for this indication in
obstetrics.
I further employed my synthetic procedure to produce new lysergic acid
compounds for which uterotonic activity was not prominent, but from which, on
the basis of their chemical structure, other types of interesting
pharmacological properties could be expected. In 1938, I produced the
twenty-fifth substance in this series of lysergic acid derivatives: lysergic
acid diethylamide, abbreviated LSD-25 (Lyserg-saure-diathylamid) for
laboratory usage.
I had planned the synthesis of this compound with the intention of obtaining a
circulatory and respiratory stimulant (an analeptic). Such stimulating
properties could be expected for lysergic acid diethylamide, because it shows
similarity in chemical structure to the analeptic already known at that time,
namely nicotinic acid diethylamide (Coramine). During the testing of LSD-25 in
the pharmacological department of Sandoz, whose director at the time was
Professor Ernst Rothlin, a strong effect on the uterus was established. It
amounted to some 70 percent of the activity of ergobasine. The research report
also noted, in passing, that the experimental animals became restless during
the narcosis. The new substance, however, aroused no special interest in our
pharmacologists and physicians; testing was therefore discontinued.
For the next five years, nothing more was heard of the substance LSD-25.
Meanwhile, my work in the ergot field advanced further in other areas. Through
the purification of ergotoxine, the starting material for lysergic acid, I
obtained, as already mentioned, the impression that this alkaloidal
preparation was not homogeneous, but was rather a mixture of different
substances. This doubt as to the homogeneity of ergotoxine was reinforced when
in its hydrogenation two distinctly different hydrogenation products were
obtained, whereas the homogeneous alkaloid ergotamine under the same condition
yielded only a single hydrogenation product (hydrogenation = introduction of
hydrogen). Extended, systematic analytical investigations of the supposed
ergotoxine mixture led ultimately to the separation of this alkaloidal
preparation into three homogeneous components. One of the three chemically
homogeneous ergotoxine alkaloids proved to be identical with an alkaloid
isolated shortly before in the production department, which A. Stoll and E.
Burckhardt had named ergocristine. The other two alkaloids were both new. The
first I named ergocornine; and for the second, the last to be isolated, which
had long remained hidden in the mother liquor, I chose the name ergokryptine
(kryptos = hidden). Later it was found that ergokryptine occurs in two
isomeric forms, which were differentiated as alfa- and beta-ergokryptine.
The solution of the ergotoxine problem was not merely scientifically
interesting, but also had great practical significance. A valuable remedy
arose from it. The three hydrogenated ergotoxine alkaloids that I produced in
the course of these investigations, dihydroergocristine, dihydroergokryptine,
and dihydroergocornine, displayed medicinally useful properties during testing
by Professor Rothlin in the pharmacological department. From these three
substances, the pharmaceutical preparation Hydergine was developed, a
medicament for improvement of peripheral circulation and cerebral function in
the control of geriatric disorders. Hydergine has proven to be an effective
remedy in geriatrics for these indications. Today it is Sandoz's most
important pharmaceutical product.
Dihydroergotamine, which I likewise produced in the course of these
investigations, has also found application in therapeutics as a circulation-
and bloodpressure-stabilizing medicament, under the trade name Dihydergot.
While today research on important projects is almost exclusively carried out
as teamwork, the investigations on ergot alkaloids described above were
conducted by myself alone. Even the further chemical steps in the evolution of
commercial preparations remained in my hands - that is, the preparation of
larger specimens for the clinical trials, and finally the perfection of the
first procedures for mass production of Methergine, Hydergine, and Dihydergot.
This even included the analytical controls for the development of the first
galenical forms of these three preparations: the ampules, liquid solutions,
and tablets. My aides at that time included a laboratory assistant, a
laboratory helper, and later in addition a second laboratory assistant and a
chemical technician. |
| |
| The solution of the ergotoxine problem had led to fruitful results, described
here only briefly, and had opened up further avenues of research. And yet I
could not forget the relatively uninteresting LSD-25. A peculiar presentiment
- the feeling that this substance could possess properties other than those
established in the first investigations - induced me, five years after the
first synthesis, to produce LSD-25 once again so that a sample could be given
to the pharmacological department for further tests. This was quite unusual;
experimental substances, as a rule, were definitely stricken from the research
program if once found to be lacking in pharmacological interest.
Nevertheless, in the spring of 1943, I repeated the synthesis of LSD-25. As in
the first synthesis, this involved the production of only a few centigrams of
the compound.
In the final step of the synthesis, during the purification and
crystallization of lysergic acid diethylamide in the form of a tartrate
(tartaric acid salt), I was interrupted in my work by unusual sensations. The
following description of this incident comes from the report that I sent at
the time to Professor Stoll:
Last Friday, April 16,1943, I was forced to interrupt my work in
the laboratory in the middle of the afternoon and proceed home,
being affected by a remarkable restlessness, combined with a slight
dizziness. At home I lay down and sank into a not unpleasant
intoxicated-like condition, characterized by an extremely stimulated
imagination. In a dreamlike state, with eyes closed (I found the
daylight to be unpleasantly glaring), I perceived an uninterrupted
stream of fantastic pictures, extraordinary shapes with intense,
kaleidoscopic play of colors. After some two hours this condition
faded away.
This was, altogether, a remarkable experience - both in its sudden onset and
its extraordinary course. It seemed to have resulted from some external toxic
influence; I surmised a connection with the substance I had been working with
at the time, lysergic acid diethylamide tartrate. But this led to another
question: how had I managed to absorb this material? Because of the known
toxicity of ergot substances, I always maintained meticulously neat work
habits. Possibly a bit of the LSD solution had contacted my fingertips during
crystallization, and a trace of the substance was absorbed through the skin.
If LSD-25 had indeed been the cause of this bizarre experience, then it must
be a substance of extraordinary potency. There seemed to be only one way of
getting to the bottom of this. I decided on a self-experiment.
Exercising extreme caution, I began the planned series of experiments with the
smallest quantity that could be expected to produce some effect, considering
the activity of the ergot alkaloids known at the time: namely, 0.25 mg (mg =
milligram = one thousandth of a gram) of lysergic acid diethylamide tartrate.
Quoted below is the entry for this experiment in my laboratory journal of
April 19, 1943. |
| |
4/19/43 16:20: 0.5 cc of 1/2 promil aqueous solution of diethylamide
tartrate orally = 0.25 mg tartrate. Taken diluted with about 10 cc
water. Tasteless.
17:00: Beginning dizziness, feeling of anxiety, visual distortions,
symptoms of paralysis, desire to laugh.
Supplement of 4/21: Home by bicycle. From 18:00- ca.20:00 most severe
crisis. (See special report.)
Here the notes in my laboratory journal cease. I was able to write the last
words only with great effort. By now it was already clear to me that LSD had
been the cause of the remarkable experience of the previous Friday, for the
altered perceptions were of the same type as before, only much more intense. I
had to struggle to speak intelligibly. I asked my laboratory assistant, who
was informed of the self-experiment, to escort me home. We went by bicycle, no
automobile being available because of wartime restrictions on their use. On
the way home, my condition began to assume threatening forms. Everything in my
field of vision wavered and was distorted as if seen in a curved mirror. I
also had the sensation of being unable to move from the spot. Nevertheless, my
assistant later told me that we had traveled very rapidly. Finally, we arrived
at home safe and sound, and I was just barely capable of asking my companion
to summon our family doctor and request milk from the neighbors.
In spite of my delirious, bewildered condition, I had brief periods of clear
and effective thinking - and chose milk as a nonspecific antidote for
poisoning.
The dizziness and sensation of fainting became so strong at times that I could
no longer hold myself erect, and had to lie down on a sofa. My surroundings
had now transformed themselves in more terrifying ways. Everything in the room
spun around, and the familiar objects and pieces of furniture assumed
grotesque, threatening forrns. They were in continuous motion, animated, as if
driven by an inner restlessness. The lady next door, whom I scarcely
recognized, brought me milk - in the course of the evening I drank more than
two liters. She was no longer Mrs. R., but rather a malevolent, insidious
witch with a colored mask.
Even worse than these demonic transformations of the outer world, were the
alterations that I perceived in myself, in my inner being. Every exertion of
my will, every attempt to put an end to the disintegration of the outer world
and the dissolution of my ego, seemed to be wasted effort. A demon had invaded
me, had taken possession of my body, mind, and soul. I jumped up and screamed,
trying to free myself from him, but then sank down again and lay helpless on
the sofa. The substance, with which I had wanted to experiment, had vanquished
me. It was the demon that scornfully triumphed over my will. I was seized by
the dreadful fear of going insane. I was taken to another world, another
place, another time. My body seemed to be without sensation, lifeless,
strange. Was I dying? Was this the transition? At times I believed myself to
be outside my body, and then perceived clearly, as an outside observer, the
complete tragedy of my situation. I had not even taken leave of my family (my
wife, with our three children had traveled that day to visit her parents, in
Lucerne). Would they ever understand that I had not experimented
thoughtlessly, irresponsibly, but rather with the utmost caution, an-d that
such a result was in no way foreseeable? My fear and despair intensified, not
only because a young family should lose its father, but also because I dreaded
leaving my chemical research work, which meant so much to me, unfinished in
the midst of fruitful, promising development. Another reflection took shape,
an idea full of bitter irony: if I was now forced to leave this world
prematurely, it was because of this Iysergic acid diethylamide that I myself
had brought forth into the world.
By the time the doctor arrived, the climax of my despondent condition had
already passed. My laboratory assistant informed him about my selfexperiment,
as I myself was not yet able to formulate a coherent sentence. He shook his
head in perplexity, after my attempts to describe the mortal danger that
threatened my body. He could detect no abnormal symptoms other than extremely
dilated pupils. Pulse, blood pressure, breathing were all normal. He saw no
reason to prescribe any medication. Instead he conveyed me to my bed and stood
watch over me. Slowly I came back from a weird, unfamiliar world to reassuring
everyday reality. The horror softened and gave way to a feeling of good
fortune and gratitude, the more normal perceptions and thoughts returned, and
I became more confident that the danger of insanity was conclusively past.
Now, little by little I could begin to enjoy the unprecedented colors and
plays of shapes that persisted behind my closed eyes. Kaleidoscopic, fantastic
images surged in on me, alternating, variegated, opening and then closing
themselves in circles and spirals, exploding in colored fountains, rearranging
and hybridizing themselves in constant flux. It was particularly remarkable
how every acoustic perception, such as the sound of a door handle or a passing
automobile, became transformed into optical perceptions. Every sound generated
a vividly changing image, with its own consistent form and color.
Late in the evening my wife returned from Lucerne. Someone had informed her by
telephone that I was suffering a mysterious breakdown. She had returned home
at once, leaving the children behind with her parents. By now, I had recovered
myself sufficiently to tell her what had happened.
Exhausted, I then slept, to awake next morning refreshed, with a clear head,
though still somewhat tired physically. A sensation of well-being and renewed
life flowed through me. Breakfast tasted delicious and gave me extraordinary
pleasure. When I later walked out into the garden, in which the sun shone now
after a spring rain, everything glistened and sparkled in a fresh light. The
world was as if newly created. All my senses vibrated in a condition of
highest sensitivity, which persisted for the entire day.
This self-experiment showed that LSD-25 behaved as a psychoactive substance
with extraordinary properties and potency. There was to my knowledge no other
known substance that evoked such profound psychic effects in such extremely
low doses, that caused such dramatic changes in human consciousness and our
experience of the inner and outer world.
What seemed even more significant was that I could remember the experience of
LSD inebriation in every detail. This could only mean that the conscious
recording function was not interrupted, even in the climax of the LSD
experience, despite the profound breakdown of the normal world view. For the
entire duration of the experiment, I had even been aware of participating in
an experiment, but despite this recognition of my condition, I could not, with
every exertion of my will, shake off the LSD world. Everything was experienced
as completely real, as alarming reality; alarming, because the picture of the
other, familiar everyday reality was still fully preserved in the memory for
comparison.
Another surprising aspect of LSD was its ability to produce such a
far-reaching, powerful state of inebriation without leaving a hangover. Quite
the contrary, on the day after the LSD experiment I felt myself to be, as
already described, in excellent physical and mental condition.
I was aware that LSD, a new active compound with such properties, would have
to be of use in pharmacology, in neurology, and especially in psychiatry, and
that it would attract the interest of concerned specialists. But at that time
I had no inkling that the new substance would also come to be used beyond
medical science, as an inebriant in the drug scene. Since my self-experiment
had revealed LSD in its terrifying, demonic aspect, the last thing I could
have expected was that this substance could ever find application as anything
approaching a pleasure drug. I failed, moreover, to recognize the meaningful
connection between LSD inebriation and spontaneous visionary experience until
much later, after further experiments, which were carried out with far lower
doses and under different conditions.
The next day I wrote to Professor Stoll the abovementioned report about my
extraordinary experience with LSD-25 and sent a copy to the director of the
pharmacological department, Professor Rothlin.
As expected, the first reaction was incredulous astonishment. Instantly a
telephone call came from the management; Professor Stoll asked: "Are you
certain you made no mistake in the weighing? Is the stated dose really
correct?" Professor Rothlin also called, asking the same question. I was
certain of this point, for I had executed the weighing and dosage with my own
hands. Yet their doubts were justified to some extent, for until then no known
substance had displayed even the slightest psychic effect in
fractionof-a-milligram doses. An active compound of such potency seemed almost
unbelievable.
Professor Rothlin himself and two of his colleagues were the first to repeat
my experiment, with only onethird of the dose I had utilized. But even at that
level, the effects were still extremely impressive, and quite fantastic. All
doubts about the statements in my report were eliminated. |
 |
| |
| |
| |
| |
| |
| |
| |
|